SCHEMBL4121857

SCHEMBL4121857

COc1ccc(CNc2ccc(Cl)cc2C(O)c2cccc(OC)c2OC)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
ALDH1A1 P00352 7/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
ABCB1 P08183 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
APLNR P35414 1/20 0.41
KDM4C Q9H3R0 2/20 0.41
TSHR P16473 10/20 0.40
MAPK1 P28482 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
POLB P06746 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
MAPT P10636 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP1A2 P05177 8/20 0.39
CYP3A4 P08684 8/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123181 0.93 TAS1R3 (0.42) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4123383 0.93 TAS1R3 (0.43) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4111042 0.92 TSHR (0.42) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4123362 0.92 ALDH1A1 (0.44) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4112997 0.92 TAS1R3 (0.39) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4119617 0.92 TAS1R3 (0.49) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4121028 0.92 TAS1R3 (0.41) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4123165 0.91 KDM4E (0.42) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4122265 0.91 TAS1R3 (0.44) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4109465 0.91 KDM4C (0.44) TAS1R3TAS1R1ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR TAS1R3 3354/4885TAS1R1 2624/4885ALDH1A1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.